Motivational Therapy for Substance Users With Depression

Depression Clinical Trial

— Aftercare  

Official title:

Motivational Therapy for Substance Users With Depression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01189799
• Other study ID #: 1K23DA020085
• Secondary ID: 1K23DA020085
• Status: Completed
• Phase: N/A
• Start date: September 2007
• Est. completion date: January 2013

Study information

• Verified date: October 2023
• Source: University of California, Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to test the incremental efficacy and outcomes of an aftercare program of Cognitive Behavioral Therapy combined with motivational therapy (CBT-MT) relative to treatment as usual (TAU) in improving depression, substance use, and healthcare outcomes in a population with drug dependence and comorbid major depressive disorder (MDD). The investigators expect that among drug-dependent patients with comorbid MDD, CBT-MT will yield better clinical outcomes relative to TAU in reducing depressive symptoms and substance use and improving healthcare outcomes during treatment. Secondary Objectives: 1. Test efficacy and outcomes of CBT-MT and TAU 2. Evaluate the differential effect of CBT-MT versus TAU on HIV-risk behavior of participants, 3. To evaluate the impact of cognitive functioning on treatment retention and outcomes, and 4. To explore additional psychosocial, demographic, and diagnostic factors (e.g., age, gender, education level, motivation for change, social support) that may be associated with treatment outcome and retention in this high need population.

Description:

This study will include approximately 80 participants randomized to either 12 weeks of motivational therapy or treatment as usual. Both treatments will meet once weekly for 60 minutes. Participants will be recruited from the Adult Partial Hospitalization program at University of California, Los Angeles. During the active treatment phase, participants will attend clinic weekly for collection of data and urine specimens. 1. For those randomly assigned to CBT-MT, they will meet with a therapist in a group format for 60-minute sessions once weekly. a. Each CBT-MT session will begin with 20 minutes of motivational therapy (MT), followed by 40 minutes of CBT content. 2. Those randomly assigned to TAU, they will attend a weekly 60-minute Dual Recovery Anonymous self-help group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: January 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 or over

2. DSM-IV diagnosis of Substance Dependence (cannabis, stimulant, opioid, or prescription drug) or DSM-IV diagnosis of Alcohol Dependence and abuse of cannabis, stimulant, opioid, or prescription drug

3. Diagnostic and Statistical Manual -IV diagnosis of lifetime Major Depressive Disorder (MDD)

4. BDI-II score of 13 or greater

Exclusion Criteria:

1. Presence of life threatening or unstable medical illness

2. Lack of proficiency in English

3. Current homelessness (unless residing in a recovery home for which contact information can be provided)

4. Psychiatric symptoms warranting safety concerns or inpatient treatment, including acute suicide risk

5. Present diagnosis of Bipolar Disorder, Schizophrenia, or Schizoaffective Disorder.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Substance Dependence
• Substance-Related Disorders

Intervention

Behavioral:
• Motivational therapy
Twelve, 60 minute weekly structured manualized therapy sessions.
• Dual Recovery Anonymous/Tx as usual
Twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.

Locations

Country	Name	City	State
United States	UCLA Integrated Substance Abuse Programs	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, Los Angeles	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Substance Use	Participants will provide a sample for a urine drug screen (UDS).; Participants will also self report substance use.	weekly during active phase and through study completion, up to 6 months
Primary	Change in Depression symptoms	-Participants will complete the Beck's Depression Inventory (BDI) to measure changes in depression symptoms over time.	weekly during intervention and through study completion, up to 6 months
Primary	Change in Healthcare utilization	-Participants will self report use of ancillary treatment and healthcare services including ER visits and hospitalizations.	weekly and at follow up, up to 6 months
Secondary	Efficacy and outcomes of CBT-MT and TAU	- Participants will complete the Addiction Severity Index to assess change in psychosocial functioning between baseline, end of treatment and follow up.	Baseline, end of treatment, and at follow up, up to 6 months
Secondary	HIV-risk behavior of participants	-Participants will complete the Risk Behavior Assessment (RBA) to measure effect of CBT-MT versus TAU on changes in HIV risk behaviors.	Baseline, end of treatment and follow up, up to 6 months
Secondary	Cognitive functioning	-Participants will complete the MicroCog and Wisconsin Card Sort Test impact of cognitive functioning on treatment retention and outcomes.	Baseline and end of treatment at 3 months post treatment